Reset IV: What the FDA Letter Means for What You Pay

This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://resetiv.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.

1. 1

   “"Semaglutide (the same ingredient in Wegovy & Ozempic)"”

2. 2

   “"Tirzepatide (the same ingredient in Zepbound & Mounjaro)"”

3. 3

   “Compounded drug products are not FDA-approved. Your claims imply that your products are the same as an FDA-approved product when they are not.”

1. 1

   Letter issued

   September 2025

2. 2

   15-working-day response window

   FDA gives the company 15 working days to respond in writing.

3. 3

   Close-out, if issued

   FDA may post one once it is satisfied the cited issues have been corrected.

resetiv.com returned a live storefront when we checked in August 2026, still trading as a Las Vegas mobile IV therapy service with published package pricing. Neither semaglutide nor tirzepatide appeared on its homepage or its peptide-therapy page at that check, though we did not review every page on the site, so this is not a confirmation that the products named in the letter were withdrawn.

This letter is the useful counter-example to the assumption that a warning letter marks out a bad actor. Nothing here concerns pricing, nothing concerns safety, and nothing concerns a claim anyone wrote as a sales pitch — FDA cited two parentheses in two product names, the sort of shorthand a shopper would read as a helpful clarification rather than a claim. It is a reminder that the presence of a letter tells you what wording FDA reviewed in one month of 2025, not how a company operates. It also shows how wide this enforcement wave was cast: a regional IV-drip service got the same letter, from the same office, on the same day as the largest telehealth brands in the country.

As of August 2026, FDA’s public tracking for this letter does not show a logged company response. Companies are not required to make a response public, and FDA does not always update this field promptly — this is not evidence Reset IV failed to respond.